Clopidogrel in systemic sclerosis

Clopidogrel in systemic sclerosis: an open labelled, proof of concept study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN63206606

Enrollment

Registered

2014-12-02

Start date

2013-12-05

Completion date

Unknown

Last updated

2018-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Systemic Sclerosis/Rheumatology Skin and Connective Tissue Diseases Systemic sclerosis

Interventions

Treatment with Clopidogrel 75mg PO daily for 1 year

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Scleroderma diagnosis based on 2012 ACR/EULAR classification criteria 2. Age over 18

Exclusion criteria

Exclusion criteria: 1. History of endocranial bleeding 2. History of gastrointestinal ulcer 3. Renal failure,EGFR less than 30ml/min based on MDRD formula

Design outcomes

Primary

Measure	Time frame
Patients will be assessed after 1 year of treatment. 1. Improvement of FVC and/or DLco more than 10% 2. Improvement of MRSS skin score more than 20%	—

Secondary

Measure	Time frame
1. Improvement of laboratory endothelial markers(s-VCAM & s-ICAM) 2. Reduction in serotonin levels in platelet poor plasma	—

Countries

Greece

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Mar 13, 2026